<DOC>
	<DOCNO>NCT01747044</DOCNO>
	<brief_summary>Fibromyalgia affect 0.7 3.3 % adult population 7-10 time woman men . In France , prevalence 1.6 % accord French study conduct 2009 published 2011 Serge Perrot et al . The definition fibromyalgia recently amend particular consideration cognitive somatic symptom , factor involve initial criterion ACR classification . Several factor favor malfunction central modulation pain poorer performance noxious inhibitory control descendant ( DNIC : diffuse noxious inhibitory control ) demonstrate . In fibromyalgia patient , DNIC ( diffuse noxious inhibitory control ) alter less pain inhibition control . Dysfunction central pain modulation widely describe literature contribute pain complained fibromyalgia . According Recommendations European League Against Rheumatism ( EULAR ) 2006 , antidepressant genuine analgesic efficacy control study . Milnacipran antidepressant know used major depressive disorder accord marketing authorization also part molecule use treatment chronic neuropathic pain fibromyalgia accord recommendation EULAR . A review include five double-blind study 4,000 participant take 100 mg 200 mg milnacipran placebo period 8 week 24 week . A moderate response obtain 40 % participant treat dose milnacipran criterion `` least 30 % pain relief '' Impression global change . Substantial improvement milnacipran compare placebo show . To date , link weaken DNIC fibromyalgia effectiveness drug treatment show . This study aim assess degree impairment DNIC fibromyalgia patient may predictive efficacy milnacipran .</brief_summary>
	<brief_title>Prospective Study Influence Diffuse Noxious Inhibitory Controls Pain Efficacy Milnacipran Fibromyalgia Therapy</brief_title>
	<detailed_description>Visit 1 Inclusion patient , Clinical examination , Evaluation pain , basal Pain cognitive test Visit 2 ( couple Visit 1 necessary ) Randomisation patient allocation treatment 1 month . Phone contact Visit 2 +7 day , + 15 day , +21 day Follow-up compliance treatment collection adverse event . Visit 3 ( follow 1 month ) Evaluation pain , Pain cognitive test End study</detailed_description>
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Milnacipran</mesh_term>
	<criteria>Patient 18 year old , Patient fibromyalgia Patient contraindication administration milnacipran , Patient concomitant spontaneous pain attributable fibromyalgia , Patient medical and/or surgical history judge investigator compatible trial .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Fibromyalgia</keyword>
	<keyword>Diffuse Noxious Inhibitory Controls</keyword>
	<keyword>Milnacipran</keyword>
</DOC>